EVAX News and Press, Evaxion Biotech A/S From 11/06/25

2025-11-06 07:37:29 ET More on Evaxion Biotech ADS Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma - Slideshow Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript ...

COPENHAGEN, Denmark, November 6, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2025 financial results. Business highlights ...

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology™ platform EVX-04 is a therapeutic cancer vaccine candidate designed for acute myeloid leukemia New data showing EVX-04 induces s...

Correcting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline. COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-ImmunologyȒ...

COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Friday October 31...

Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 million Total gross inflow of cash of $14.7 million since the end of the second quarter 2025 Evaxion now has cash on hand to fund its operations and R&D programs int...

2025-10-27 08:13:57 ET More on Evaxion Biotech ADS Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript Evaxion A/S (EVAX) Presents at BioTechX Europe 2025 - Slideshow Evaxion A/S (EVAX) Out-Licenses Vaccine Ca...

Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership deals Her more than 30 years of experience include leadership roles in the UK and US, from early research th...

2025-10-22 17:13:48 ET Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma October 22, 2025 10:30 AM EDT... Read the full article on Seeking Alpha For further details see: Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI...

A look at the top 10 most actives in the United States Rani Therapeutics Holdings Inc. (RANI) rose 248.3% to $1.64 on volume of 482,613,416 shares Beyond Meat Inc. (BYND) rose 24.2% to $0.6456 on volume of 419,584,353 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 1.0% to $4...